Cargando…

Weight loss and persistence with liraglutide 3.0 mg by obesity class in the real‐world effectiveness study in Canada

OBJECTIVE: Liraglutide 3.0 mg is associated with clinically significant weight loss in clinical trials, but real‐world data are lacking. In this analysis, weight loss and persistence outcomes with liraglutide 3.0 mg were assessed across obesity classes, in a real‐world clinical setting. METHODS: Sec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wharton, Sean, Haase, Christiane L., Kamran, Elham, Liu, Aiden, Mancini, Johanna, Neish, Drew, Pakseresht, Arash, Power, G Sarah, Christensen, Rebecca A. G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Short Communications
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7448201/ https://www.ncbi.nlm.nih.gov/pubmed/32874678 http://dx.doi.org/10.1002/osp4.420

Ejemplares similares

Real‐world persistence with liraglutide 3.0 mg for weight management and the SaxendaCare® patient support program
por: Wharton, Sean, et al.
Publicado: (2020)

Real‐World Clinical Effectiveness of Liraglutide 3.0 mg for Weight Management in Canada
por: Wharton, Sean, et al.
Publicado: (2019)

Liraglutide 3.0 mg for the management of insufficient weight loss or excessive weight regain post‐bariatric surgery
por: Wharton, Sean, et al.
Publicado: (2019)

The burden of obesity in the current world and the new treatments available: focus on liraglutide 3.0 mg
por: Mancini, Marcio C., et al.
Publicado: (2017)

Exposure–response analyses of liraglutide 3.0 mg for weight management
por: Wilding, J. P. H., et al.
Publicado: (2016)

Liraglutide 3.0 mg for Weight Management: A Population Pharmacokinetic Analysis
por: Overgaard, Rune V., et al.
Publicado: (2016)

A pilot randomized controlled trial of liraglutide 3.0 mg for binge eating disorder
por: Allison, Kelly C., et al.
Publicado: (2022)

Efficacy of liraglutide 3.0 mg treatment on weight loss in patients with weight regain after bariatric surgery
por: Muratori, Fabrizio, et al.
Publicado: (2022)

Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management
por: Kolotkin, R. L., et al.
Publicado: (2016)

The Efficacy and Safety of Liraglutide 3.0 mg for Weight Management in Obese Non-Diabetic Saudi Outpatients
por: Albaker, Waleed, et al.
Publicado: (2021)

Adherence to and Dropout from Liraglutide 3.0 mg Obesity Treatment in a Real-World Setting
por: Ko, Hae-Jin, et al.
Publicado: (2022)

Marked weight loss on liraglutide 3.0 mg: Real‐life experience of a Swiss cohort with obesity
por: Santini, Sara, et al.
Publicado: (2022)

Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial
por: Blackman, A, et al.
Publicado: (2016)

Impact of Treatment with GLP1 Receptor Agonists, Liraglutide 3.0 mg and Semaglutide 1.0 mg, While on a Waiting List for Bariatric Surgery
por: Rubio-Herrera, Miguel A., et al.
Publicado: (2023)

Early Weight Loss with Liraglutide 3.0 mg Predicts 1‐Year Weight Loss and is Associated with Improvements in Clinical Markers
por: Fujioka, Ken, et al.
Publicado: (2016)

Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial
por: Wadden, Thomas A., et al.
Publicado: (2020)

Efficacy and Safety of Liraglutide 3.0 mg in Patients with Overweight and Obese with or without Diabetes: A Systematic Review and Meta-Analysis
por: Konwar, Mahanjit, et al.
Publicado: (2022)

Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials
por: O'Neil, Patrick M., et al.
Publicado: (2017)

Improvements in health‐related quality of life over 3 years with liraglutide 3.0 mg compared with placebo in participants with overweight or obesity
por: Kolotkin, R. L., et al.
Publicado: (2017)

Impact of dose‐escalation schemes and drug discontinuation on weight loss outcomes with liraglutide 3.0 mg: A model‐based approach
por: Papathanasiou, Theodoros, et al.
Publicado: (2020)

Improving Adherence to Weight‐Loss Medication (Liraglutide 3.0 mg) Using Mobile Phone Text Messaging and Healthcare Professional Support
por: Li, Ang, et al.
Publicado: (2020)

Liraglutide 3.0 mg and mental health: can psychiatric symptoms be associated to adherence to therapy? Insights from a clinical audit
por: Tempia Valenta, Silvia, et al.
Publicado: (2023)

A randomized trial to investigate the efficacy and safety of once‐daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg
por: Seino, Yutaka, et al.
Publicado: (2022)

Efficacy and safety of liraglutide 3.0 mg for weight management are similar across races: subgroup analysis across the SCALE and phase II randomized trials
por: Ard, J., et al.
Publicado: (2016)

Perceptions of barriers to effective obesity management in Canada: Results from the ACTION study
por: Sharma, Arya M., et al.
Publicado: (2019)

Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial
por: Garvey, W. Timothy, et al.
Publicado: (2020)

Safety and Efficacy of Liraglutide, 3.0 mg, Once Daily vs Placebo in Patients With Poor Weight Loss Following Metabolic Surgery: The BARI-OPTIMISE Randomized Clinical Trial
por: Mok, Jessica, et al.
Publicado: (2023)

"Safe" Coulomb Excitation of $^{30}$Mg
por: Niedermaier, O., et al.
Publicado: (2004)

SAT-097 Weight Loss With Liraglutide 3.0 Mg Versus Placebo For Individuals Who Adhere To The Trial Drug: A Secondary Analysis From SCALE IBT
por: Shaw Tronieri, Jena, et al.
Publicado: (2019)

SAT-099 Liraglutide 3.0 mg as an Adjunct to Intensive Behavior Therapy in Individuals with Obesity: SCALE IBT 56-Week Randomized, Double-Blind, Placebo-Controlled Trial
por: Wadden, Thomas, et al.
Publicado: (2019)

Liraglutide-Induced Hepatotoxicity
por: Maor, Yaakov, et al.
Publicado: (2021)

SAT-105 Weight Loss As Determined By Adherence To Reduced Caloric Diet, Increased Physical Activity, Liraglutide 3.0 Mg and Placebo: A Sub-analysis Of The SCALE IBT Trial
por: Shaw Tronieri, Jena, et al.
Publicado: (2019)

The effectiveness and safety of pharmaceuticals to manage excess weight post-bariatric surgery: a systematic literature review
por: Wharton, Sean, et al.
Publicado: (2019)

Predictors of Weight Loss and Weight Gain in Weight Management Patients during the COVID-19 Pandemic
por: Kuk, Jennifer L., et al.
Publicado: (2021)

High-sensitivity study of levels in $^{30}Al$ following β decay of $^{30}Mg$
por: Olaizola, B, et al.
Publicado: (2016)

MON-120 Effect of Weight Loss on Physical Function Measured by the 6-Minute Walking Distance Test in Individuals with Obesity: Results from the SCALE IBT Trial of Liraglutide 3.0 Mg
por: Rubino, Domenica, et al.
Publicado: (2019)

Effectiveness and cost of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in obesity services (STRIVE study): study protocol of an open-label, real-world, randomised, controlled trial
por: Papamargaritis, Dimitris, et al.
Publicado: (2020)

Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Liraglutide 1.8 mg: A Health Economic Analysis in the UK
por: Evans, Marc, et al.
Publicado: (2023)

Exploring the Island of Inversion with the d ($^{30}$Mg, p) $^{31}$Mg reaction
por: Bildstein, Vinzenz
Publicado: (2013)

Cost-Effectiveness Analysis of Incretin Therapy for Type 2 Diabetes in Spain: 1.8 mg Liraglutide Versus Sitagliptin
por: Pérez, Antonio, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_rmr9k3c3v244psmhneu46giqpe